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Abstract
Background: Activation of the complement system has been implicated in both acute and chronic states of
neurodegeneration. However, a detailed understanding of this complex network of interacting components is
still lacking.
Methods: Large-scale global expression profiling in a rat F2(DAxPVG) intercross identified a strong cis-regulatory
influence on the local expression of complement receptor 2 (Cr2) in the spinal cord after ventral root avulsion (VRA).
Expression of Cr2 in the spinal cord was studied in a separate cohort of DA and PVG rats at different time-points after
VRA, and also following sciatic nerve transection (SNT) in the same strains. Consequently, Cr2−/− mice and Wt controls
were used to further explore the role of Cr2 in the spinal cord following SNT. The in vivo experiments were
complemented by astrocyte and microglia cell cultures.
Results: Expression of Cr2 in naïve spinal cord was low but strongly up regulated at 5–7 days after both
VRA and SNT. Levels of Cr2 expression, as well as astrocyte activation, was higher in PVG rats than DA rats
following both VRA and SNT. Subsequent in vitro studies proposed astrocytes as the main source of Cr2
expression. A functional role for Cr2 is suggested by the finding that transgenic mice lacking Cr2 displayed
increased loss of synaptic nerve terminals following nerve injury. We also detected increased levels of
soluble CR2 (sCR2) in the cerebrospinal fluid of rats following VRA.
Conclusions: These results demonstrate that local expression of Cr2 in the central nervous system is part
of the axotomy reaction and is suggested to modulate subsequent complement mediated effects.
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Background
The complement system, a part of the innate arm of
immunity, is activated in various inflammatory condi-
tions [1]. A number of studies have also documented
complement activity in the CNS both in acute conditions
like stroke [2] and traumatic brain injury (TBI) [3], as well
as in chronic diseases like multiple sclerosis (MS) [4, 5]
and Alzheimer’s disease (AD) [6], all characterized by
a varying degree of inflammatory features present in
the tissue. The complement system consists of a large
number of components, many of which are primarily
produced in the liver, but some are also expressed within
the central nervous system CNS [7, 8]. Activation of the
complement cascade is needed for a wide range of impor-
tant defense functions, including cell-lysis, chemotaxia,
opsonisation, and immune cell stimulation [9, 10] but
may also aggravate tissue damage [3, 5, 6, 11]. The
mechanisms underlying complement activation in the
CNS are complex and still not fully understood. The
intricate structure of the system not only offers flexibility
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and efficiency, but also provides a basis for multiple points
of possible dysregulation [12].A prerequisite for the agility
of complement responses is a wide distribution of com-
plement receptors, present on a range of cell types in-
cluding macrophages [13], T cells [14], B cells [15],
microglia, and astrocytes [16, 17]. Furthermore, many of
the complement receptors exist in both membrane-bound
and secreted forms, for instance, both complement recep-
tors 1 (CR1) and 2 (CR2) exist in soluble forms: sCR1 [18]
and sCR2 [19], respectively. Thus, the functional conse-
quences of complement receptor expression depends
not only on cellular localization, but also if the protein
is anchored to the membrane or released into the extra-
cellular space. Thus, soluble complement receptors can
inhibit the cascade by binding complement proteins
[12], a fact which has been explored in complement
directed therapies [20].
We have previously described strain-dependent differ-
ences in the local expression of the upstream complement
components C1q and C3 in the spinal cord of the inbred
DA and PVG rat strains following a standardized nerve
injury, where differences in expression of C1q correlated
with subsequent nerve cell loss [21]. Furthermore, we
recently identified distinct regulatory pathways of several
complement components, including C1q and C3, in a
F2(DAxPVG) intercross using the same nerve injury
model [22]. The aim of the current study was to
characterize and genetically map and characterize any
possible differences in the local expression of comple-
ment receptors in this F2(DAxPVG) intercross.
Methods
Animals and operations
The inbred MHC congenic rat strain Dark Agouti-RT1av1
(DA) and the inbred MHC congenic Piebald Viral
Glaxo-RT1av1 hereafter called PVG were bred and main-
tained in the in-house breeding facility under specific
pathogen-free conditions and climate-controlled environ-
ment with 12 h light/dark cycles and fed standard rodent
chow and water ad libitum. The F2(DAxPVG) intercross
has been described previously [22–24]. In brief, DA/PVG
males and females were crossed generating two groups of
offspring (F1), in turn mated reciprocally generating
four groups of F2 progeny from which a total of 144
animals were used. Both female and male rats and an
equal number of rats from each of the four groups
were studied.
All animals from the F2 intercross were at an age of
9–12 weeks subjected to unilateral avulsion of the left
lumbar L3–L5 ventral roots, as described in Additional
file 1. Five days post-operatively, the animals were eutha-
nized with CO2 and perfused via the ascending aorta
with ice-cold PBS containing heparin (LEO Pharma AB,
Malmö, Sweden) (10 IE/ml). Spinal cords were dissected
and examined using a dissection microscope to verify the
completeness of the lesion and exclude any visible signs of
hemorrhage or necrotic zones. After removal of the scar
on the superficial part of the spinal cord, the ipsilateral
ventral quadrant of L3, L4, and L5 was dissected out, and
then snap-frozen for subsequent mRNA extraction.
The G12 (DAxPVG) advanced intercross line (AIL)
was developed by continued structured breeding from a
G10 AIL previously established [25]. A cohort of 161
G12 animals were subjected to ventral root avulsion
(VRA), with a 5-day post-operative survival and the L3
segment used in the expression studies.
An additional cohort consisting of 72 DA and PVG
rats was used to analyze the kinetics following VRA. The
animals were divided into five experimental groups of
5–7 individuals with 1, 3, 5, 7, or 14 days post VRA sur-
vival and one naïve (un-operated) control group. The L3
segments were taken for mRNA preparation and the
L4–L5 segments were taken en bloc and snap-frozen for
further preparation/sectioning.
DA and PVG animals (n = 22) were operated with left
sided sciatic nerve transection (SNT) below the obtu-
rator tendon. Half the group was euthanized and per-
fused with ice-cold PBS with heparin 5 days after
operation, and the left-sided L4 segment was taken for
further RT-PCR analysis, with the right L4 segment as
control. The remaining group was perfused with Lana’s
fixative at the same post-operative survival. These spinal
cords were dissected, kept in 4 % PFA overnight, and then
transferred to 10 % sucrose in PBS before mounting and
sectioning of the L3–L5 segments.
Cr2−/− mice (Balb/c background) were kindly provided
by Professor Birgitta Heyman, Department of Medical
Biochemistry and Microbiology, Uppsala University, and
have previously been described [26]. Control Balb/c mice
were purchased from Charles River (Wilmington, MA).
Cr2−/− mice and Balb/c mice (n = 27) were operated with
left-sided SNT using the same surgical procedure as in
the rats. At 5 days post-operative survival, 11 animals
were euthanized with CO2 and perfused with PBS, with
dissection of the L4 segments for RT-PCR analysis, as
in the rats. At the same post-operative survival, the
remaining 16 animals were perfused with Lana’s fixa-
tive and the L3–L5 segments taken as described for
the SNT rats.
CSF samples were obtained from seven PVG animals,
three naïve and four animals with a 5-day post-operative
survival after VRA. The posterior cranial fossa was defined,
and a fine needle (BD Valu-set 23G, BD Pharmingen)
attached to a 1-ml syringe was used to carefully aspi-
rate CSF from the cerebellomedullary cistern using a
stereotactic frame. The CSF obtained (100–150 μl from
each animal) was immediately put on dry-ice and stored
at −80 °C. The CSF samples were diluted 1:4 and then
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analyzed for presence of rat sCD21 with sandwich ELISA
technique according to the manufacturer’s instructions
(USCN Life, Wuhan, China, cat.nr E0750r). All tissues
were stored at −80 °C.
DNA preparation and genotyping
Genomic DNA was extracted from rat tail tips according
to methods previously described [27]. Polymorphic micro-
satellite markers were selected from the Rat Genome
Database (http://rgd.mcw.edu) and the Ensembl database
(www.ensembl.org). The F2 intercross was genotyped
with 113 microsatellite markers evenly distributed
across the genome, with an average distance of 20 cM
based on previous knowledge of optimum spacing [28].
The successful genotyping rate was 95.3 %. Details of
the F2 genotyping have been described previously [22].
The G12 intercross was densely genotyped in the region
of the Cr2 gene and the peak marker from the F2 inter-
cross, using four microsatellite markers (D13Rat192,
D13Rat159, D13Rat141, and D13Rat49), with an average
marker distance of 4 cM. The Cr2 gene is located at the
end of RNO13 and all markers were located up stream of
Cr2, which is why four markers were considered to give
sufficient genomic resolution.
RNA and cDNA preparation
RNA and cDNA was prepared using standard method-
ology as previously described [22].
All steps were performed under RNAse-free conditions.
The tissue samples consisted of the injured L3 ventral
cord quadrant from VRA animals in the kinetic study
and the G12 cohort, while the corresponding L4 ventral
cord quadrant was used in the F2 cohort. From the
SNT animals, both mice and rats, both the ipsi- and
contralateral L4 segments were used.
RT-PCR
Real-time PCR was conducted using a three-step PCR
protocol using IQ5 and CFX384 software (Bio-Rad,
Hercules CA). All primers were designed with Beacon
Designer 5.0 software (Bio-Rad) and tested for speci-
ficity by running the amplified product on gels with
silver staining. Two house-keeping genes were used to
normalize the levels of mRNA expression of the studied
transcripts; hypoxanthine guanine phosphoribosyl transfer-
ase (Hprt) and glyceraldehyde 3-phosphate dehydrogenase
(Gapdh). Normalized expression levels were calculated
with the IQ5 or CFX 384 software. We chose C1qb as
a marker for C1q expression since it was previously
shown to correlate with nerve cell loss [21]. All primer
sequences are presented in Tables 1 and 2. The Cr2
gene is disrupted but not completely depleted in the
Cr2−/− which explains the small expression of the gene
seen even in the Cr2−/−.
Microarray hybridization
RNA from 144 L4 ventral cord quadrants from F2
animals were used for microarray hybridization using
Affymetrix Rat gene 1.0 ST Array chips (Affymetrix,
Santa Clara, CA). See Additional file 1 for details. The
microarray data is available in MIAME-compliant (minimal
information about a microarray experiment) format at the
ArrayExpress Database (http://www.ebi.ac.uk/arrayexpress)
under accession code E-MTAB-303.
eQTL analysis and gene expression network construction
An expression quantitative trait locus (eQTL) is a
gene region that regulates gene expression rather
than a functional trait or disease. eQTL mapping is
performed by combining expression data from global
gene expression profiling with a complete linkage map,
derived from whole-genome mapping using for instance
microsatellite or SNP markers dispersed throughout the
genome. This enables the identification of large num-
bers of expression QTLs and the study of co-regulated
transcripts at various positions of the genome. eQTLs
are classified into cis- or trans-acting according to the
distance between the locations of genetic marker and
Table 1 Sequences for rat RT-PCR primers
Primer name Forward sequence Reverse sequence
Gapdh TCAACTACATGGTCTACATGTTCCAG TCCCATTCTCAGCCTTGACTG
Hprt CTCATGGACTGATTATGGACAGGAC GCAGGTCAGCAAAGAACTTATAGCC
C1qb TCATAGAACACGAGGATTCCATACA GACCCAGTACAGCTGCTTTGG
C3 GGGAGCCCCATGTACTCCAT GGGACGTCACCCTGAGCAT
Gfap AAGCACGAGGCTAATGACTATCG AAGGACTCGTTCGTGCCG
Mrf-1 GGAGGCCTTCAAGACGAAGTAC AGCATTCGCTTCAAGGACATAATA
CD11b ATCCGTAAAGTAGTGAGAGAAC TCTGCCTCAGGAATGACATC
Cr2 (CD21) GGCTACCTTATGGCTGGAGAG AGAGTCACAGTAGTCCCAAACC
Cr1 (CD35) GGCTTGAGACCGCTGTGAGG TGGATTCATCAGTTGGATTTATAGGTTTGG
CD19 CTGTTGAGGACTGGTGGATGGATAG CTCGCTGTCTGGCTCTTCATAGG
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the affected transcript. For a cis-acting QTL, the
expression is regulated from the same position as the
gene is located in the genome.
The current eQTL mapping has been described
previously [22]. In brief, microarray gene expression
data were normalized using the RMA algorithm [29],
implemented in the Bioconductor package “oligo.”
Raw expression intensities were background corrected,
quantile normalized, log2 transformed, and summarized
on the level of transcript clusters. Transcript annotation
was taken from the biocondutor package “ragene10sttran-
scriptcluster.db.” eQTLs were mapped for all transcript
clusters using the QTL reaper software [30] against the
113 genomic markers, and 106 permutations were per-
formed in order to assess genome-wide significance of
eQTLs; p < 0.01 at genome-wide level was considered
significant. The eQTLs were classified into cis- or
trans-acting according to the distance between the
locations of genetic marker and the affected transcript.
If the distance was smaller than 20 Mb, we assumed
cis- and otherwise trans-regulation. The identified Cr2
cluster (D13Rat49) was analyzed for enrichment of
specific pathways and expression patterns using the
Biocondutor package GOstats [31]. To enable identifi-
cation of strongly connected hub genes in the eQTL
gene expression network, we applied a graphical
Gaussian model (GGM) and for each cluster of trans-
regulated transcripts, we constructed gene expression
networks as previously described reporting significant
edges with FDR < 0.1 [32].
Primary astrocyte and microglia cultures
Primary astrocytes and microglia were isolated from
adult PVG brains of 10-week-old rats. A detailed proto-
col can be found in Additional file 1. The astrocytes and
microglia were left unstimulated (only DMEM/F12
complete medium, supplemented with 10 % heat-
inactivated FCS, penicillin-streptomycin 100 units/ml,
100 μg/ml) or stimulated with recombinant rat TNF-α
(R&D Systems, Minneapolis, MN) at the concentration
20 ng/ml for 24 h after which the cells were lysed for
RNA extraction and subsequent RT-PCR expressional
analysis.
Immunohistochemistry and quantification of
synaptophysin immunoreactivity
Rat and mouse spinal cord sections were serially cut
(14 μm) on a cryostat (Leica Microsystems, Wetzlar,
Germany) at the level of the L4 segment. Detailed pro-
tocols can be found in the Additional file 1. For rat anti-
sera directed against synaptophysin (rabbit anti-rat 1:200,
Invitrogen, Carlsbad, CA), GFAP (mouse anti-rat, 1:400,
Sigma), Iba1 (rabbit anti-rat, 1:200, Wako, Richmond, VA),
or C3 (mouse anti-rat, 1:100 Abbiotec, San Diego, CA) was
used together with appropriate flourophore-conjugated
secondary antibody (Cy3 donkey anti-rabbit 1:500, Jackson
Immuno Research, West Grove, PA; Alexa Fluor 488
donkey anti-rabbit, 1:150 and Alexa Fluor 594, goat anti-
mouse, 1:300, both from Invitrogen). For mouse, the
following antisera were used: GFAP (mouse anti-rat,
1:400, Sigma), CD68 (rat anti-mouse, 1:100, Abcam,
Cambridge, UK), and CD21 (rabbit anti-mouse 1:200,
Abcam) with the following secondary antibodies; Alexa
488 donkey anti-rat 1:150 and Alexa 568, donkey anti-
rabbit 1:300 (Invitrogen).
Sections were examined in a Zeiss LSM 5 Pascal
confocal laser scanning microscope (Carl Zeiss GmbH,
Göttingen, Germany) or a Leica DM RBE microscope
system (Leica). Semiquantitative measurements of immu-
noreactivity were carried out in ImageJ (NIH, Bethesda,
MD) on confocal images. The immunoreactivity in the
ventral horn of the spinal cord was compared to the
corresponding contralateral side in the same spinal
cord section. The images were captured in the optical
plane with the maximal immunoreactivity, and all settings
for compared images were identical. At least four spinal
cord sections from each animal were measured, and the
mean ipsilateral/contralateral signal ratio for each animal
was used for statistical analysis.
Table 2 Sequences for mouse RT-PCR primers
Primer name Forward sequence Reverse sequence
Gapdh TCAACTACATGGTCTACATGTTCCAG TCCCATTCTCAGCCTTGACTG
Hprt CTCATGGACTGATTATGGACAGGAC GCAGGTCAGCAAAGAACTTATAGCC
C1qb AGAGCAAGAGGAGGTTGTTCAC GCAGGAAGATGGTGTTGGATAGG
C3 GCTGCTGTCTTCAATCACTTCATC GCCTCTTGCCTCTTCTCTATGC
CD11b CCCAGAGGCTCTCAGAGAATGTC CTTCATCTTCTGAAAGTCAATGTT
Cr2 (CD21) AACCTGGCTATTTGCTCACTGG ACTTTCCTGGATGTTCACACTGG
Gfap GGTAAGATGACTGAGCGGATGG TCGTGGTAAAGACTGTGGAGATG
Mrf-1 GGAGGCCTTCAAGACGAAGTAC AGCATTCGGTTCAAGGACATAATA
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Statistical analysis
The software program R 2.6.0 was used to carry out statis-
tical analyses and create all graphs depicting eQTL
localization using the package qtl1.14-2. LOD > 3.3
corresponds to p < 0.0001 [33]. One-way ANOVA cal-
culated with GraphPad Prism 5.0 (San Diego, CA) were
carried out on RT-PCR and protein data; results are
represented as mean ± SEM. Unpaired t test was used to
assess differences in immunoreactivity (GraphPad Prism
5.0). Correlations between genes in the co-expression
network in the F2 intercross were calculated using
Pearson’s algorithm assuming equal distribution and vi-
sualized graphically using linear regression plots, also
in GraphPad Prism 5.0. In general, p < 0.05 was consid-
ered statistically significant, except for in the micro-
array analysis where p < 0.01 was used.
Study approval
All experiments in this study were approved by the eth-
ical committee for animal experimentation (Stockholms
Norra Djurförsöksetiska Nämnd), Stockholm, Sweden,
under ethical permits N42/06, 225/08, N32/09, N343/10,
and N122/11.
Results
eQTL mapping of complement and complement
receptors in the rat spinal cord following ventral root
avulsion
By global expression profiling in an F2(DAxPVG)
intercross, we recently identified new pathways regu-
lating complement expression following a standard-
ized nerve injury model, ventral root avulsion (VRA)
[22]. This data set here was employed to analyze the
expression of the complement receptors Cr1-4. In the F2
cohort (n = 144), differences in expression of Cr2 (also
called CD21) displayed an extremely strong cis-regulation
from an expression quantitative trait locus (eQTL) on
chromosome 13. Indeed, the Cr2 transcript was one of
the most strongly regulated eQTLs in the whole data-
set, which contained more than 27,000 transcripts, with
a logarithm of odds (LOD) score of over 13 (genome-
wide p value <10−6) for the peak marker D13Rat49
located at 104.4 Mb, with higher expression driven by
PVG alleles (Fig. 1a–c). Cr2 itself is located at 111.1 Mb.
Expression of the CD11b subunit of Cr3 (also called
Itgam) was cis-regulated from D1Arb21 on chromosome 1
(187.1 Mb) (p value <0.001) and was higher in animals
with DA alleles. Expression of the CD11c subunit of Cr4
(also called Itgax) was cis-regulated (p < 0.001) from
D1Rat56, chromosome 1 at 172.9 Mb, with higher expres-
sion driven by PVG alleles. Differences in Cr1 (CD35)
expression did not map anywhere in the genome. Based
on these results, Cr2 was selected as a candidate for
further study given the extremely strong monogenic
influence regulating its expression. In mice, but not
in rats or humans, Cr1 and Cr2 are splice variants of
the same gene [34]. Since mice are used in conse-
quent experiments, we characterized Cr1 expression
in the rats for comparative purposes.
Expression of Cr2 following VRA correlates positively with
anti-inflammatory and growth promoting genes and
negatively with pro-inflammatory genes
Thirty genes were co-regulated with Cr2 from D13Rat49,
and a co-expression gene network was constructed by ana-
lyzing pair-wise co-variation in expression between all
these transcripts (Fig. 2). The cluster was enriched for
genes involved in leucocyte activation (p < 0.01) and co-
factor binding (p < 0.001). There were multiple transcripts
directly co-regulated with Cr2, where those associated
with pro-inflammatory action, such as lymphocyte acti-
vation, correlated negatively with Cr2 expression, for
example CD48, CD244, F11r, and Fcgr2a (Additional
file 2: Table S1). Conversely, Sgpl1, recently demon-
strated to have anti-inflammatory effects [35], and Meis3,
involved in neuronal development [36] and cellular sur-
vival [37], displayed a positive correlation with Cr2 expres-
sion (Additional file 2: Table S1).
Confirmation of a cis-acting control of Cr2 expression
Microsatellite markers in the F2 intercross were inter-
spaced with an average distance of 20 cM. In order to
both fine-map the cis-acting effect on Cr2 expression, as
well as to reproduce the microarray expression data in
an independent experiment, spinal cords from 161
animals from an advanced G12(DAxPVG) intercross
subjected to VRA were analyzed with RT-PCR. High-
resolution linkage analysis in the G12 animals was per-
formed by dense microsatellite mapping around the
peak marker from the F2 intercross. As the Cr2 gene is
located yet more downstream than the most distal
polymorphic marker available, the observed >2 LOD-
score drop corresponds to a CI of 99.8 % [38]. The rep-
lication of the finding that Cr2 expression is regulated
from the region of the microsatellite marker closest to
the Cr2 gene (D13Rat49, 104.4 Mb) confirms the cis-
regulatory effect (Fig. 1d). As in the F2 intercross,
D13Rat49 PVG alleles gave rise to higher Cr2 expres-
sion (Fig. 1e).
Kinetics of Cr1-2 expression and glial response following
ventral root avulsion
The kinetics of Cr2 expression following VRA was
assessed using RT-PCR in DA and PVG rats, demo-
nstrating peak expression 7 days after injury, with
significantly higher expression in PVG rats at most
time-points (Fig. 1f ). Cr1 expression showed a late up
regulation in both strains at 14 days post-injury without
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major strain differences (Additional file 3: Figure S1A).
Since Cr2 is highly expressed by B cells, in complex with
CD19, we also determined CD19 mRNA levels. Expres-
sion of CD19 was barely measurable and without discern-
ible strain differences, suggesting minimal infiltration of B
cells (Additional file 4: Figure S2A).
Glial activation occurring after injury was assessed
using glial fibrillary acidic protein (Gfap), microglia
response factor-1 (Mrf-1), and CD11b (a subunit of
Cr3) as markers of astrocyte and microglia activation,
respectively. Expression of both Gfap (Additional file 3:
Figure S1B) and Mrf-1 (Additional file 3: Figure S1C)
increased in a bimodal fashion, with an initial rise at 1
and 3 days, followed by a second increase 7 days after
injury. Expression of Gfap was higher in the PVG
strain at 3 and 7 days after injury (Additional file 3:
Figure S1B). Expression of Mrf-1 did not differ between
strains, suggesting a limited strain influence on general
state of microglial activation (Additional file 3: Figure
S1C). In contrast, expression of CD11b was significantly
increased in DA compared to PVG at most time-points,
suggesting an increase of a CD11b+ microglia subset in
the DA strain (Additional file 4: Figure S2D).
Complement expression following sciatic nerve injury is
associated with loss of synaptic terminals
Sciatic nerve transection (SNT) induces a local, albeit
milder than after VRA, inflammatory response in the
area of axotomized cell bodies within the CNS [39, 40].
DA and PVG rats were subjected to SNT with quanti-
fication of multiple transcripts in the ipsi- and contra-
lateral side of the spinal L4 level 5 days after surgery.
Expression of Gfap was more pronounced in the PVG
strain (Fig. 3a–d), while microglial markers Mrf-1 and
CD11b were higher in DA (Fig. 3e, f), also confirmed by
more intense Iba1 immunolabeling (Fig. 3g–j). Expression
of CD19 was not increased after SNT, but levels were
generally higher in DA (Additional file 4: Figure S2B).
Fig. 1 Genetic analysis of Cr2 expression following ventral root avulsion. Regulation of Cr2 expression following VRA is under strong genetic
control. Global expressional profiling of injured spinal cords from a F2(DAxPVG) rat intercross (n = 144) reveals a cis-acting expression QTL at
the end of chromosome 13 (a–b the black box marks the genetic area around D13Rat49 subsequently fine-mapped in the G12). D13Rat49 PVG
alleles are associated with higher Cr2 expression (c). The cis-acting control of Cr2 expression after nerve injury was confirmed in a G12(DAxPVG)
advanced intercross line (n = 163) (d). Again, PVG alleles gave rise to higher expression (e). A kinetic study of the injury response in DA and PVG
animals with different post-operative survival following VRA revealed that Cr2 is expressed at very low levels in naïve spinal cord but strongly up
regulated following injury, particular in PVG (f). n = 5–7 per strain per time-point following VRA. LOD > 3.3 corresponds to p < 0.0001, *p < 0.05,
**p < 0.01, and ***p < 0.001. In c and d, the results are presented as mean ± SD and in f as mean ± SEM
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Complement expression is associated with loss of synaptic
nerve terminals following both VRA and SNT [22, 41].
C1q and C3 were both up regulated following SNT, with
higher expression in DA compared to PVG rats (Fig. 4a, b).
Expression of Cr1 was not affected in either strain after in-
jury, but levels were generally higher in PVG (Fig. 4c). In
contrast, Cr2 displayed a conspicuous up regulation in
PVG but not in DA (Fig. 4d). Quantification of synaptic
density performed 5 days post SNT demonstrated a
more pronounced loss of synaptic nerve terminals in
DA compared to PVG rats (Fig. 4e–g). Double labeling
with antisera against C3 and synaptophysin showed C3
deposition in close proximity to synapthopysin in juxta-
position to axotomized motor neurons (Fig. 4h–j).
Fig. 2 Gene expression network of transcripts regulated from D13Rat49 in the F2(DAxPVG) intercross. A co-expression gene network was
constructed from all transcripts regulated from D13Rat49. All 31 genes regulated from D13Rat49 were closely interconnected; the association
between the genes is based on pair-wise co-variation of expression levels. Cis-regulated genes are marked with red circles, the other genes are
regulated in trans. The Cr2 transcript is surrounded by a green ring. Cr2 expression correlated negatively with expression of multiple genes with
pro-inflammatory action, for example CD48, CD244, F11r, and Fcgr2a all involved in lymphocyte activation. Conversely, Cr2 expression correlated
positively with Sgpl1 and Meis3, genes involved in anti-inflammatory and cellular survival processes. n = 144 F2(DAxPVG) rats
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Cr2 protects from synaptic loss following sciatic nerve
transection
As CR2 is known to bind different C3 fragments [42]
and C3 was up regulated after injury, we sought to
identify a functional role of the increased Cr2 expression
after nerve injury. Thus, Balb/c and Cr2−/− mice on
Balb/c background were subjected to SNT. There was
no difference in the up regulation of Gfap expression
between wild type and Cr2−/− animals 5 days after surgery
(Fig. 5a), but GFAP immunoreactivity was increased in
wild type compared to Cr2−/− (Fig. 5b–d). Both strains
displayed up regulation of Mrf-1 and CD11b, as signs of
microglia activation (Fig. 5e, f ), with a trend for higher
expression levels of both genes and significantly more
intense Iba1 immunolabeling in Cr2−/− mice (Fig. 5g–j).
C1q was strongly up regulated in both strains
(Fig. 6a), while C3 tended to be up regulated solely in
the Cr2−/− strain (p = 0.048, t test) (Fig. 6b). As
expected, expression of Cr2 was significantly up regu-
lated in wild-type Balb/c mice following SNT but not
in Cr2−/− (Fig. 6c). Assessment of synaptic density in
the dorsolateral part of the ventral horn revealed
significantly increased loss of synaptophysin immuno-
reactivity following injury in Cr2−/− compared to wild
type, suggesting a more pronounced loss of synaptic
nerve terminals in the absence of CR2 (Fig. 6d–f ).
Cr2 is expressed by astrocytes
In a recent study, 13 antibodies specific for CR2 were
evaluated for immunohistochemistry in the CNS; how-
ever, none yielded distinct stainings [43]. This is in line
with our experience, as also our immunohistochemical
assessments of CR2 gave a diffuse staining pattern
(not shown). Previous data has suggested astrocytes
as the source of CR2 in the CNS [17, 43]. We there-
fore established cultures of rat astrocytes, as well as
microglia which are known to express CR3/CD11b [44],
to assess comparative expression patterns. Cultured cells
were left unstimulated or stimulated with TNF-α with
determination of Cr2 expression assessed with RT-PCR.
Cr2 expression was readily detectable in astrocytes, but
not microglia, and was not affected by TNF-α (Fig. 7a).
In contrast, CD11b expression was much higher in
microglia compared to astrocytes, and increased follow-
ing TNF-α stimulation (Fig. 7b).
Soluble CR2 can be detected in CSF of rats following
ventral root avulsion
CR2 also exists in a soluble form, sCR2 (sCD21),
present in blood [45–48]. The existence of Cr2 in the
CNS, as demonstrated by RT-PCR, in combination with
the difficulty of staining for CR2 prompted us to inves-
tigate the presence of sCR2 also in the CSF. Protein
ELISA measurements of sCR2 in CSF from naive and
VRA-operated PVG animals showed detectable levels,
with up regulation following injury, in concordance
with expression data (Fig. 7c).
Discussion
Using an unbiased genetic approach, we find here a
strong naturally occurring cis-acting genetic influence
on the local expression of Cr2 in the spinal cord
following nerve root injury. Our experimental data
support the notion that CR2, previously mostly studied
Fig. 3 Glial activation in DA and PVG rats following sciatic nerve transection. Sciatic nerve transaction in DA and PVG rats leads to increased Gfap
expression without discernible strain differences (a). Quantification of GFAP immunoreactivity in the dorsal spinal motor nucleus demonstrates more
pronounced astrocyte activation in the PVG compared to DA strain (b–d). More intense microglia activation occurs in the DA strain following SNT, as
assessed by expression of Mrf-1 and CD11b (e–f), as well as by quantifying Iba1 immunoreactivity (g–j). IL ipsilateral, CL contralateral. Scale bar equals
40 μm. n = 5 + 5 RT-PCR, 6 + 6 IHC; *p < 0.05, **p < 0.01, and ***p < 0.001. The results are represented as mean ± SEM
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in context of B cell biology, is an integral part of the
inherent CNS response to injury and that it may
modulate synaptic plasticity by regulating upstream
complement activity. Hypothetically, this could be
done by secreted/shed soluble CR2.
Mapping of the genetic effect was carried out in a
standardized nerve injury model, VRA, where motor
axons are severed at the interface between the peripheral
and central nervous systems, resulting in substantial loss
of injured nerve cells. For technical reasons, a more
peripheral nerve injury model, SNT, was used in mice.
SNT also induces inflammatory activation of microglia
and astrocytes in the vicinity of the lesioned motor
neurons, albeit with more limited loss of axotomized
cells than VRA [40, 49, 50]. The so-called axon reaction
has been a subject of study for more than a century,
initially focusing on the characteristic morphological
changes occurring in injured cells [51]. Subsequent
Fig. 4 Complement expression is associated with synapse loss following sciatic nerve transection in rat. Both C1q and C3 are up regulated in
DA and PVG rats following SNT but with significantly higher levels in DA (a and b). Similar to VRA, Cr1 was not regulated after injury in either
strain (c), whereas Cr2 was strongly up regulated in PVG (d). Increased complement expression following SNT is associated with loss of synaptic
terminals in the ventral horn, as measured by a ratio of synaptophysin immunoreactivity in the dorsal spinal motor nucleus of the injured and
control sides (e and f). Loss of synapses is more pronounced in the DA strain (g). C3 immunoreactivity is present as a diffuse labeling as well as
a more distinct signal on the cell bodies of some motor neurons (h). C3 labeling is found in close proximity with synaptophysin on the contour
of motor neurons visualized at higher magnification (i–j). White arrow heads show motor neurons distinguishable by their large nuclei (h–j).
IL ipsilateral, CL contralateral. Scale bar equals 40 μm in e, f, and h and 10 μm in i and j. n = 5 + 5 RT-PCR and 6 + 6 IHC, all at 5 days post SNT,
*p < 0.05, **p < 0.01, and ***p < 0.001. The results are represented as mean ± SEM
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research has shown alterations in electrical activity at
the level of the cell body believed to be the caused
by elimination of afferent synaptic input to lesioned
neurons [52]. After acute mechanical injuries, the elimin-
ation of synaptic input has been assumed to be beneficial,
perhaps by limiting excitotoxic stress [50, 53]. However,
more recent studies suggest that reduced loss of synapses
after SNT or VRA is associated with improved functional
outcome [41, 54]. Likely, the molecular systems regulating
plasticity of nerve terminals have to be finely tuned as
excessive loss of synaptic connectivity may be an impor-
tant biological substrate for chronic neurodegenerative
diseases, which has been demonstrated to occur as an
early disease-related phenomenon [55, 56]. An increasing
body of evidence suggests that the complement sys-
tem plays an important role for synaptic plasticity.
Thus, upstream complement proteins such as C1q
and C3 mediate synaptic remodeling during develop-
ment [57, 58]. They are also implicated in normal aging,
since a dramatic increase in C1q occurs in the brain of old
mice and humans [59], as well as in neurodegenerative
diseases such as AD and Parkinson’s disease, and also MS
[6, 60]. The notion that dysregulation of the complement
system occurs upstream rather than downstream of an
inherent neurodegenerative process is supported by the
observation that genetic variability in both Clusterin and
CR1 is associated to risk of late-onset AD [61, 62].
Although the functional consequences of complement
activation in chronic neurodegenerative disease need to be
defined more in detail, it seems plausible that excessive
activation may exaggerate a neurodegenerative process.
The recent genetic association of CR1 to AD [62] led
us to examine any possible naturally occurring strain
differences in expression of the four most studied comple-
ment receptors, Cr1-4, after nerve injury. Cr2-4 could all
be shown to be regulated from distinct genetic regions,
with the most striking finding for Cr2, which was subject
to a very strong monogenic cis-acting regulation. In con-
trast, Cr1 was not regulated by injury in the rat.
CR2 has been studied mostly in context of B cell
immunology, where it is expressed on mature B cells
and forms a complex with CD19 and CD81. This tri-
molecular formation functions as a co-receptor complex,
where CR2 binds opsonized C3d and antigen-bound IgM
resulting in an enhanced antigenic B cell response [63].
However, it is unlikely that B cells cause the observed
strain differences in Cr2 expression due to the low
expression of its B cell binding partners. The role of
CR2 in the CNS has received little attention, but
expression of CR2 has been previously reported on acti-
vated astrocytes and has been demonstrated to regulate
neurogenesis in the mouse [17, 43].
Microglia are suggested to be involved in the emoval
of synapses occurring after CNS injury, and complement
is known to increase their phagocytic properties [58, 64].
In the rat strains studied here, the microglia response
was stronger in DA than PVG after both SNT and VRA.
Interestingly, only CD11b (Cr3), but not Mrf-1, displayed
Fig. 5 Glial activation in Balb/c and Balb/c Cr2−/− mice following sciatic nerve transection. Expression of Gfap increased in the spinal cords of both
Balb/c wild-type (WT) and Cr2−/− mice following SNT but without strain differences (a). Quantification of GFAP immunoreactivity the dorsal spinal
motor nucleus demonstrates more pronounced astrocyte activation in WT compared to Cr2−/− (b–d). Expression of Mrf-1 and CD11b are strongly
up regulated in both WT and Cr2−/−, without significant differences between strains at the mRNA level (e–f). In contrast, quantification of Iba1 in the
dorsal spinal motor nucleus demonstrates increased immunolabeling signal in Cr2−/− compared to WT thus opposite to GFAP (g–j). IL ipsilateral, CL
contralateral. Scale bar equals 40 μm. n = 6 + 5 RT-PCR, 8 + 8 IHC, *p < 0.05, **p < 0.01, and ***p < 0.001. The results are represented as mean ± SEM
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higher levels in DA, suggesting the possible existence of
microglia subsets with different phagocytic abilities. This
may have functional implications as mice deficient for Cr3
(CD11b/CD18) display reduced loss of synapses during
development of the visual system [58].
The similar expression pattern of Cr2 and Gfap, and
the Cr2 expression in the astrocyte cultures suggest
astrocytes as a source of locally expressed Cr2 in the
CNS. The existence primarily of a soluble form could
explain the difficulty to stain for CR2 in the CNS [43].
We examined this by measuring sCR2 levels with Elisa
in CSF, which verified the presence of soluble CR2 and
that levels increased following injury. The increase in
sCR2 may not only reflect increased transcription, but
Fig. 6 Complement receptor 2 protects against synapse loss following sciatic nerve transection. Expression of C1q is up regulated in mice
following SNT, without discernible strain differences (a). C3 demonstrates a strong trend towards increased expression in the injured side
ofthe cord in Cr2−/− but not WT mice (p = 0.048, t test), but does not quite reach significance (b). Cr2 is significantly up regulated following
injury in WT mice (c). Assessment of synaptic density by quantification of synaptophysin immunolabeling signal demonstrates increased loss
in Cr2−/−, suggesting that CR2 protects from synapse elimination following nerve injury (d–f). The white box shows a motor neuron on the
control and injured sides, respectively, where the dense synaptic synaptophysin-labeled aura surrounding the cell body is lost on the
axotomized cell (e and f). IL ipsilateral, CL contralateral. Scale bar equals 40 μm. n = 6 + 5 RT-PCR, 8 + 8 IHC; *p < 0.05, **p < 0.01, and
***p < 0.001. The results are represented as mean ± SEM
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can be the result of increased shedding of the CR2 ecto-
domain, which corresponds to sCR2, due to oxidative
stress triggered by VRA [24, 65].
The results presented herein suggest that activated
PVG astrocytes produce more CR2/sCR2, in turn of
possible relevance for protecting the integrity of synap-
tic networks. This interpretation is supported by results
obtained in Cr2−/− mice, which display increased loss of
synaptophysin-labeled synaptic terminals after SNT.
Possibly, deficiency in CR2 also affects glial activation after
nerve injury, with enhanced microglia and reduced astro-
cyte activation, as supported by quantification of the
microglia immunolabeling signal in the axotomized sciatic
motor pool. This is also supported by the constructed
gene expression network, where Cr2 correlates posi-
tively with anti-inflammatory and negatively with pro-
inflammatory transcripts, and by previous findings,
where sCR2 was shown to modulate monocyte activity
[66]. CR2 binds to C3dg and iC3b, both breakdown
products of C3 [67]. Thus, increased sCR2 after injury
may serve a regulatory role as a binder of deposited C3
fragments in the area of inflammation. However, it is
also possible that CR2 could have a more complex role
in altering the balance or activation steps of the C3
activation/cleavage cascade, with multiple active break-
down products. For instance, iC3b is the primary ligand
for CR3 (CD11b/CD18) [68], whereas C3b is not bound
by CR3 [69], but instead by CR1 [70]. This suggests that
increased levels of sCR2 in context of nerve injury leads
to decreased iC3b generation, which in turn attenuates
the process of synaptic loss, as the CR3 (CD11b/CD18)
positive microglia have been shown to be involved in
removal of synapses [58]. It could also explain the
increased microglia activation seen in the Cr2−/− mice,
as iC3b binding to CR3 can contribute to increased
microglia activation [44].
The complexity of complement activity is illustrated
by a recent study, which may at first seem contra-
dictory to ours, since Cr2−/− mice demonstrated
improved initial outcome after experimental TBI [71].
However, this model differs considerably from the ones
used here, since in TBI there is a dramatic loss of blood-
brain barrier function leading to influx of immune cells
and complement proteins from the systemic circulation.
Furthermore, it is difficult to dissociate the effect of
targeting both CR1 and CR2, since in mice, but not
in humans and rats, the two proteins are coded in
the same gene. It should also be underscored that the
presence or expression of complement proteins is not
synonymous with complement activation, as defined
by the release of complement protein fragments with
immune signaling properties and activation of the
complement cascade [12]. Lastly, it is also of import-
ance to note the different roles of soluble as com-
pared to membrane bound forms of complement
receptors, where they in one form may be activating
and in the other regulatory.
Conclusions
We identify here a strong naturally occurring genetic vari-
ation acting on Cr2 in the rat, which affects the local
expression of Cr2 in the spinal cord following both prox-
imal and peripheral nerve injury as well as the levels of
sCR2 in CSF. In mice lacking Cr2, peripheral nerve injury
leads to increased microglia activation and more pro-
nounced loss of nerve terminals. These results suggest a
role for CR2 in regulating complement-mediated effects
in the CNS. The role of CR2/sCR2 may also be relevant to
Fig. 7 Cr2 is expressed by astrocytes in vitro, and levels of soluble CR2 are increased in cerebrospinal fluid of rats following ventral root
avulsion. The expression pattern of Cr2 was similar to that of Gfap suggesting astrocytes as a likely source. To confirm that astrocytes and not microglia
were the main source of Cr2 expression, cultures of both glia types were generated from adult PVG rats and stimulated with TNF-α. Cr2 expression was
not detectable in microglia, whereas Cr2 was expressed by astrocytes although TNF-α stimulation did not lead to a significant increase
in levels (a). CD11b expression was 100- to 1000-fold higher in microglia as compared to astrocytes and increased following TNF-α
stimulation (b). CSF was collected from PVG rats subjected to VRA. Levels of soluble CR2, sCR2, were increased in injured compared
to healthy rats, as measured with Elisa (c). *p < 0.05, **p < 0.01, and ***p < 0.001, the in vitro experiments were repeated three times
with equal results. The results are represented as mean ± SEM
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explore in other settings of injury to the CNS as comple-
ment expression and/or activation is a common feature in
several both acute and chronic CNS diseases.
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